The organoids were exploited to assess the cell-killing effects of B7-H3-targeted chimeric antigen receptor (CAR) T cells and antibody-DM1 conjugate, revealing that B7-H3 might be a promising target for antibody-drug conjugate therapy against craniopharyngioma (70). This evidence concerns the gene CD276 and craniopharyngioma.